Samsung Bioepis starts SBE303 trial: what it means for Samsung Epis stock

Published on 10/19/2026 at 00:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The SBE303 program entered Phase 1 on October 12, 2026, targeting Nectin-4. For Samsung Epis stock, this means the next report date is October 28, 2026.

Pipeline and reporting dates

Samsung Bioepis began the SBE303 Phase 1 trial on October 12, 2026.
Second-quarter 2026 revenue was KRW 391.90 billion, below the KRW 455.50 billion forecast.
Samsung Epis Holdings is scheduled to report on October 28, 2026.

Samsung Epis, KR70126Z0002, Illustration mit AI erstellt.

Samsung Epis Holdings (KR70126Z0002) is tied to a new Phase 1 clinical program after its wholly owned subsidiary Samsung Bioepis began testing SBE303 on October 12, 2026. The candidate is the subsidiary's first novel antibody-drug conjugate and targets Nectin-4 in advanced solid tumors, according to ET Net.

What does SBE303 mean?

The program expands Samsung Bioepis beyond its established biosimilar pipeline into a novel drug candidate. The open-label, multicenter first-in-human study will assess safety, tolerability and efficacy in participants with advanced refractory solid tumors, with Nectin-4 linked to urothelial, lung and breast cancers in the announcement.

Three events shape the pipeline

On July 24, 2026, Samsung Bioepis reported second-quarter revenue of KRW 391.90 billion and net income of KRW 85.81 billion, compared with revenue expectations of KRW 455.50 billion, according to Investing.com. On October 1, 2026, Samsung Bioepis expanded its Teva partnership to as many as six potential biosimilar candidates, including SB41 and SB44, as Business Wire reported. On October 12, 2026, the company began the SBE303 Phase 1 trial, making the clinical program the latest dated development.

When is the next report?

Samsung Epis Holdings is scheduled to publish its next report on October 28, 2026, according to TradingView. That date will give investors the next quantified check on whether the operating business can improve on the second-quarter revenue result and advance its 2026 pipeline plans.

Stock context in Korean won

Samsung Epis Holdings was last at KRW 331,500 on the Korea Exchange on October 16, 2026 at 3:30 p.m. KST. Its market capitalization was KRW 8.2 trillion on that date, while the company's sector classification is healthcare and its industry is biotechnology.

Clinical pipeline meets earnings date

The SBE303 study adds a research milestone before the October reporting date, but clinical development remains an early-stage process. The upcoming report therefore matters because it can place the new program beside a measurable operating result.